Table 2.
Univariate and multivariate analyses of progression-free survival in advanced gastric cancer patients receiving immunotherapy and chemotherapy
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (≥ 60vs. < 60 years) | 1.210 (0.856–1.712) | 0.280 | ||
| Sex (male vs. female) | 0.802 (0.538–1.195) | 0.278 | ||
| Drinking history (yes vs. no) | 0.986 (0.678–1.435) | 0.942 | ||
| ECOG PS (0–1 vs. 2) | 0.798 (0.566–1.124) | 0.197 | ||
| Stage (III vs. IV) | 0.723 (0.497–1.052) | 0.090 | ||
| Differentiation (well or moderate vs. poor) | 1.157 (0.806–1.662) | 0.430 | ||
| PD-1+CD8+Tn % (< 21.5 vs. ≥ 21.5) | 1.273(0.901–1.797) | 0.171 | ||
| PD-L1 CPS (< 5 vs. ≥ 5) | 3.538(2.297–5.450) | < 0.001 | 3.052 (1.909–4.879) | < 0.001 |
| PD-1+CD8+T % (< 21.0 vs. ≥ 21.0) | 9.178(5.592–15.06) | < 0.001 | 8.124 (4.532–14.56) | < 0.001 |
| PD-1+CD8+Tm % (< 64.3 vs. ≥ 64.3) | 4.096 (2.740–6.121) | < 0.001 | 3.551 (2.077–6.070) | < 0.001 |
| PD-1+CD8+T/PD-1+CD4+T ratio(< 0.669 vs. 0.669) | 2.137 (1.500–3.043) | < 0.001 | 1.780 (1.178–2.690) | 0.006 |
PD-1+CD8+T PD-1+CD8+ T cells, PD-1+CD8+Tm memory PD-1+CD8+ T cells, PD-1+CD4+T PD-1+CD4+ T cells, CPS combined positive score, ECOG PS Eastern Cooperative Oncology Group Performance Status